NASDAQ:TCRR - TCR2 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.29
  • Forecasted Upside: 81.80 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$23.81
▲ +0.01 (0.04%)
1 month | 3 months | 12 months
Get New TCR2 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.29
▲ +81.80% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for TCR2 Therapeutics in the last 3 months. The average price target is $43.29, with a high forecast of $56.00 and a low forecast of $32.00. The average price target represents a 81.80% upside from the last price of $23.81.
Buy
The current consensus among 8 investment analysts is to buy stock in TCR2 Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2021MizuhoReiterated RatingBuy$51.00High
i
3/17/2021SVB LeerinkLower Price TargetOutperform$41.00 ➝ $34.00N/A
i
3/12/2021MizuhoLower Price TargetBuy$58.00 ➝ $51.00Medium
i
3/11/2021BMO Capital MarketsLower Price TargetOutperform$65.00 ➝ $56.00Low
i
3/11/2021Piper SandlerBoost Price TargetOverweight$45.00 ➝ $55.00Medium
i
3/11/2021SVB LeerinkLower Price TargetOutperform$41.00 ➝ $34.00Low
i
12/14/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $45.00High
i
12/14/2020BMO Capital MarketsBoost Price Target$46.00 ➝ $65.00Low
i
12/14/2020HC WainwrightBoost Price TargetBuy$32.00 ➝ $37.00High
i
Rating by Robert Burns at HC Wainwright
12/13/2020MizuhoReiterated RatingBuy$33.00High
i
11/30/2020Roth CapitalBoost Price TargetBuy$35.00 ➝ $38.00Low
i
Rating by T. Butler at Roth Capital
8/20/2020MizuhoInitiated CoverageBuyMedium
i
8/13/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $32.00High
i
Rating by Robert Burns at HC Wainwright
8/12/2020Truist FinancialInitiated CoverageBuyHigh
i
8/12/2020SVB LeerinkLower Price TargetOutperform$26.00 ➝ $25.00High
i
Rating by J. Chang at SVB Leerink LLC
8/12/2020Piper SandlerInitiated CoverageOverweight$35.00Low
i
7/27/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $33.00High
i
Rating by Robert Burns at HC Wainwright
7/27/2020Roth CapitalUpgradeNeutral ➝ Buy$16.00 ➝ $35.00High
i
Rating by T. Butler at Roth Capital
7/27/2020WedbushBoost Price TargetOutperform$25.00 ➝ $32.00High
i
Rating by D. Nierengarten at Wedbush
6/23/2020HC WainwrightReiterated RatingBuy$19.00High
i
Rating by Robert Burns at HC Wainwright
5/18/2020HC WainwrightReiterated RatingBuy$19.00High
i
Rating by Robert Burns at HC Wainwright
3/31/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by R. Selvaraju at HC Wainwright
3/30/2020WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
3/30/2020SVB LeerinkReiterated RatingOutperformHigh
i
Rating by J. Chang at SVB Leerink LLC
12/11/2019HC WainwrightReiterated RatingBuy$19.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/13/2019HC WainwrightReiterated RatingBuy$19.00High
i
Rating by R. Selvaraju at HC Wainwright
11/4/2019HC WainwrightInitiated CoverageBuy$19.00Medium
i
Rating by R. Selvaraju at HC Wainwright
5/31/2019Roth CapitalInitiated CoverageNeutral$16.00High
i
Rating by T. Butler at Roth Capital
3/11/2019SVB LeerinkInitiated CoverageOutperform$27.00High
i
Rating by J. Chang at SVB Leerink LLC
3/11/2019WedbushInitiated CoverageOutperform ➝ Outperform$28.00 ➝ $28.00High
i
Rating by D. Nierengarten at Wedbush
3/11/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$31.00High
i
3/11/2019BMO Capital MarketsInitiated CoverageOutperform$37.00High
i
(Data available from 4/22/2016 forward)
TCR2 Therapeutics logo
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $23.81
$23.48
$24.02

50 Day Range

MA: $23.83
$20.38
$28.11

52 Week Range

Now: $23.81
$8.63
$35.86

Volume

1,498 shs

Average Volume

551,093 shs

Market Capitalization

$908.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13

Frequently Asked Questions

What sell-side analysts currently cover shares of TCR2 Therapeutics?

The following Wall Street sell-side analysts have issued research reports on TCR2 Therapeutics in the last twelve months: BMO Capital Markets, HC Wainwright, Mizuho, Piper Sandler, Roth Capital, SVB Leerink LLC, Truist Financial Co., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for TCRR.

What is the current price target for TCR2 Therapeutics?

7 Wall Street analysts have set twelve-month price targets for TCR2 Therapeutics in the last year. Their average twelve-month price target is $43.29, suggesting a possible upside of 81.6%. BMO Capital Markets has the highest price target set, predicting TCRR will reach $56.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $32.00 for TCR2 Therapeutics in the next year.
View the latest price targets for TCRR.

What is the current consensus analyst rating for TCR2 Therapeutics?

TCR2 Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCRR will outperform the market and that investors should add to their positions of TCR2 Therapeutics.
View the latest ratings for TCRR.

What other companies compete with TCR2 Therapeutics?

How do I contact TCR2 Therapeutics' investor relations team?

TCR2 Therapeutics' physical mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company's listed phone number is 617-949-5200 and its investor relations email address is [email protected] The official website for TCR2 Therapeutics is www.tcr2.com.